Get started
NRX Pharmaceuticals, Inc.NN

NRX Pharmaceuticals, Inc.

2.01USDR
+0.07+3.61%
Last update at 23:00 GMT
1.95USD
−0.06−2.99%
No tradesPost-marketLast update at 23:12 GMT
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

NRXP chart


Full chart

NRXP upcoming earnings


Next report date
≈
May 20
Report period
Q1 2025
EPS estimate
−0.30 USD
Revenue estimate
‪5.00 M‬ USD

Key stats


Market capitalization
‪34.00 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.41 USD
Net income (FY)
‪−25.13 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪14.03 M‬
Beta (1Y)
−0.22

About NRX Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jonathan C. Javitt
Website
nrxpharma.com
Headquarters
Wilmington
Founded
2017
FIGI
BBG00JCWDN63
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Financials


Performance
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−10.00 M‬‬
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬
‪‪8.00 M‬‬
‪‪12.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:May 20, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.80‬
‪−0.60‬
‪−0.40‬
‪−0.20‬
‪0.00‬
Actual
Estimate

NRXP news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NRXP is 2.01 USD — it has increased by 3.61% in the past 24 hours. Watch NRX Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NRX Pharmaceuticals, Inc. stocks are traded under the ticker NRXP.
NRXP stock has fallen by −3.48% compared to the previous week, the month change is a −13.78% fall, over the last year NRX Pharmaceuticals, Inc. has showed a −59.23% decrease.
We've gathered analysts' opinions on NRX Pharmaceuticals, Inc. future price: according to them, NRXP price has a max estimate of 31.00 USD and a min estimate of 18.00 USD. Watch NRXP chart and read a more detailed NRX Pharmaceuticals, Inc. stock forecast: see what analysts think of NRX Pharmaceuticals, Inc. and suggest that you do with its stocks.
NRXP reached its all-time high on Dec 22, 2020 with the price of 769.90 USD, and its all-time low was 1.10 USD and was reached on Oct 16, 2024. View more price dynamics on NRXP chart.
See other stocks reaching their highest and lowest prices.
NRXP stock is 9.52% volatile and has beta coefficient of −0.22. Track NRX Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is NRX Pharmaceuticals, Inc. there?
Today NRX Pharmaceuticals, Inc. has the market capitalization of ‪32.82 M‬, it has decreased by −0.48% over the last week.
Yes, you can track NRX Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NRX Pharmaceuticals, Inc. is going to release the next earnings report on May 20, 2025. Keep track of upcoming events with our Earnings Calendar.
NRXP earnings for the last quarter are −0.71 USD per share, whereas the estimation was −0.37 USD resulting in a −94.22% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about NRX Pharmaceuticals, Inc. earnings.
NRX Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪5.00 M‬ USD.
NRXP net income for the last quarter is ‪−9.08 M‬ USD, while the quarter before that showed ‪−1.62 M‬ USD of net income which accounts for −459.33% change. Track more NRX Pharmaceuticals, Inc. financial stats to get the full picture.
No, NRXP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NRXP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NRX Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NRX Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NRX Pharmaceuticals, Inc. stock shows the sell signal. See more of NRX Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.